Fetal hemoglobin induction is a key point in the management of sickle cell disease (SCD). We report the case of a kidney transplant recipient with SCD who was treated with everolimus, a mammalian target of rapamycin inhibitor. At 10 months after initiating therapy, the patient's fetal hemoglobin level was dramatically increased (from 4.8% to 15%) and there was excellent tolerance to treatment.
Keywords: anemia; clinical research/practice; everolimus; immunosuppressant; kidney disease; kidney transplantation/nephrology; mechanistic target of rapamycin.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.